inner Roche Banner

Interactive Agenda Click on the ABSTRACT button to see details for each item

TUESDAY SEPTEMBER 14

8:30a - 6:00p

REGISTRATION

1:30p - 5:00p
PEPTIDE SHOWCASE
This session features short presentations from companies involved in the development of peptide therapeutics or peptide related technologies. A full list of companies will be listed soon.

5:30p - 6:30p

OPENING NIGHT RECEPTION


WEDNESDAY SEPTEMBER 15

7:30a - 8:30a

BREAKFAST

8:30a – 11:25a
SESSION IA – PEPTIDES IN THE CLINIC
Shk Peptides For The Treatment Of Autoimmune Disease
Shawn Iadonato, Chief Scientific Officer Kineta Bio
Oral Delivery of Peptides using GIPET® Technology
Tom Leonard,Vice President & Chief Scientific Officer Merrion Pharmaceuticals
Development Of Xen2174, A Novel Intrathecal Analgesic (Abstract not yet available)
Peter Schmidt, Product Development Manager Xenome Ltd
Guanylate Cyclase-C Agonists as a New Class of Drug Candidates for GI disorders and Inflammatory Bowel Disease
Kunwar Shailubhai, Chief Scientific Officer Synergy Pharmaceuticals

11:25a – 12:25p

KEYNOTE ADDRESS
Stephen BH Kent - Peptides for Pleasure and for Profit

12:25p – 1:25p

LUNCH

1:25p – 4:30p

SESSION II – DRUG DELIVERY AND FORMULATION
The Role Of Peptide Properties During Microencapsulation And Extended-Release From Bioresorbable Polymers
Tom Tice, Vice-President Research Surmodics Inc
Are today's medicinal chemists better prepared to design therapeutic peptides that exhibit good oral bioavailability?
Ronald T. Borchardt , Solon E. Summerfield Distinguished Professor The University Of Kansas
TPE, A Unique Formulation Based Technology Enabling Oral Delivery Of Macromolecules
Roni Mamluk , Chief Operating Officer Chiasma
PEGylation: a successful strategy in parenteral drug delivery
Francesco M. Veronese , Professor, Applied Pharmaceutical Chemistry Padua University

6:00p – 7:00p

MEIENHOFER AWARD PRESENTATION

7:00p – 9:00p

GALA DINNER AT THE RED LION INN


THURSDAY SEPTEMBER 16

7:00a – 8:00a

BREAKFAST

8:00a – 12:20p

SESSION IB – PEPTIDES IN THE CLINIC
Development Of A Nonapeptide (Syn1002) For The Treatment Of Autoimmune Diseases And Neuropathic Pain
Jamal Temsamani, Vice-President R&D CLL Pharma
An HDL mimetic peptide that stimulates cellular cholesterol efflux(Working Title)(Abstract not yet available)
Jan Johannson, Artery Therapeutics
SESSION III – CELL PENETRATING PEPTIDES AND TISSUE TARGETING
Pepducins: Novel Lipopeptide Allosteric Modulators Of Gpcr Signaling
Steve Hunt, Chief Scientific Officer Anchor Therapeutics
Targeted Delivery of Bioactive Cell Penetrating Peptides: Implications for Anti-cancer Therapy
John Howl, Professor of Molecular Pharmacology University of Wolverhampton
Ensemblins: A New Class Of Therapeutic Macrocycles
Nicholas Terrett, Chief Scientific Officer Ensemble Discovery Corp.
Cyclotides, a novel natural peptide scaffold for drug discovery
Julio Camarero, Associate Professor fo Pharmacology Univ. of Southern California

12:20p – 1:20p

LUNCH

1:20p – 3:20p

SESSION V – ADVANCES IN PEPTIDE CHEMISTRY AND ANALYTICS
Peptides On Synthetic Scaffolds For Mimicry Of Proteins Towards Synthetic Vaccines And Beyond
Rob M.J. Liskamp , Professor Utrecht University
Analytical Challenges On Pegylated Peptide API
Ping Zhuang , Research Fellow Merck and Co.

3:20p – 5:30p

POSTER SESSION

6:00p – 8:00p

NETWORKING RECEPTION